v3.25.4
Stock Option Plan and Stock-Based Compensation (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2025
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]    
Summary of Common Stock Available for Issuance  
The following table summarizes the activity in total shares of common stock available for issuance under the 2020 Plan:
 
    
Shares

Available for

Grant
 
Balance, December 31, 2022
     189,771  
Shares added
     220,375  
Granted
     (17,071 ) 
Forfeited
     28,205  
  
 
 
 
Balance, December 31, 2023
     421,280  
  
 
 
 
Shares added
     625,571  
Granted
     (680,690 ) 
Forfeited
     31,493  
  
 
 
 
Balance, December 31, 2024
     397,654  
  
 
 
 
Summary of Effects of Stock-Based Compensation
The following table summarizes the effects of stock-based compensation on cost of sales, research and development, and sales, general and administrative expenses granted under the Plans (in thousands) for the three and nine months ended September 30, 2025 and 2024:
 
    
Three months ended
September 30,
    
Nine months ended
September 30,
 
    
2025
    
2024
    
2025
    
2024
 
Cost of sales
   $ 26      $ 178      $ 126      $ 279  
Research and development
   $ 261        873        980        2,021  
Sales, general and administrative
   $ 1,781        1,071        2,578        2,011  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 2,068      $ 2,122      $ 3,684      $ 4,311  
  
 
 
    
 
 
    
 
 
    
 
 
 
The following table summarizes the effects of stock-based compensation on cost of sales, research and development, and sales, general and administrative expenses granted under the Plans (in thousands) for the years ended December 31, 2024 and 2023, respectively:
 
    
2024
    
2023
 
Cost of sales
   $ 356      $ 147  
Research and development
     2,416        1,350  
Sales, general and administrative
     2,402        1,126  
  
 
 
    
 
 
 
Total
   $ 5,174      $ 2,623  
  
 
 
    
 
 
 
Summary of Black-Scholes Option Pricing Model  
The fair value for the Company’s options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 
    
Years Ended December 31,
 
    
2024
   
2023
 
Risk-free interest rate
     4.16 %      3.74 % 
Expected life of the options
     5.47 years       6.01 years  
Dividend rate
     0 %      0 % 
Volatility
     54.51 %      52.74 % 
Fair value per share of common stock
   $ 12.60     $ 30.52  
Summary of Outstanding Options that are Vesting  
Additional information regarding outstanding options that are vesting, expected to vest, or exercisable as of December 31, 2024, is as follows:
 
    
Number of

Options
    
Weighted-

Average

Price Per

Share
    
Weighted-

Average

Exercise

Price
    
Weighted-

Average

Remaining

Contractual

Life (Years)
 
Options outstanding at December 31, 2022
     1,809,829      $ 7.56      $ 15.12        7.03  
Options granted
     8,143      $ 16.52      $ 30.52        —   
Options exercised
     (23,101 )     $ 5.88      $ 12.04        —   
Options forfeited
     (33,887 )     $ 13.72      $ 27.16        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Options outstanding at December 31, 2023
     1,760,984      $ 7.28      $ 14.84        6.03  
Options granted
     1,377,527      $ 10.64      $ 12.60        —   
Options exercised
     (78,377 )     $ 8.68      $ 10.92        —   
Options forfeited
     (831,282 )     $ 0.56      $ 22.96        —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Options outstanding at December 31, 2024
     2,228,853      $ 7.84      $ 10.64        6.23  
Vested and expected to vest
     2,223,748      $ 7.84      $ 10.64        6.23  
Exercisable
     1,791,956      $ 7.56      $ 10.08        5.53